Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DPS29T
|
|||
| Drug Name |
ORIC-944
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Prostate cancer [ICD-11: 2C82.0; ICD-9: 185] | Phase 1 | [1] | |
| Company |
ORIC Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Embryonic ectoderm development protein (EED) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05413421) An Open-Label, Phase 1/1b, Study of ORIC-944 in Patients With Metastatic Prostate Cancer. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of ORIC Pharmaceuticals | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.